A PIQRAY patient shares her inspiring story on Dr. Phil

PIQRAY® (alpelisib) tablets + fulvestrant

See how testing led to this treatment option for one patient.

Watch now to see Anne, a post-menopausal woman with HR+, HER2- metastatic breast cancer, share her story with Dr. Phil. Anne is joined by her medical oncologist, Dr Hope Rugo, Professor of Medicine and Director of Breast Oncology and Clinical Trials Education at University of California San Fransico. Anne and Dr Rugo discovered that Anne’s PIK3CA gene had a mutation, following progression on hormone therapy, which qualified Anne for treatment with PIQRAY® (alpelisib) tablets. Individual results may vary.


About 40% of people with HR+, HER2- metastatic breast cancer have a PIK3CA mutation, which has been linked to cancer growth. PIQRAY works by specifically targeting proteins made from an abnormal or mutated PIK3CA gene. If you find out you have this specific mutation, PIQRAY may offer you a more targeted treatment option.


PIQRAY affects cancer cells, but can also affect healthy cells. Although PIQRAY has been studied in people with HR+, HER2- mBC, how PIQRAY works has only been demonstrated in laboratory studies.